DIA.MI - DiaSorin S.p.A.
Milan - Milan Delayed Price. Currency in EUR
At close: 05:35PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 98.12 |
| Open | 98.90 |
| Bid | 98.98 x 0 |
| Ask | 99.00 x 0 |
| Day's Range | 97.90 - 99.24 |
| 52 Week Range | 94.28 - 143.80 |
| Volume | |
| Avg. Volume | 166,602 |
| Market Cap | 5.29B |
| Beta (5Y Monthly) | 0.13 |
| PE Ratio (TTM) | 28.90 |
| EPS (TTM) | 3.42 |
| Earnings Date | Jul 27, 2023 |
| Forward Dividend & Yield | 1.10 (1.12%) |
| Ex-Dividend Date | May 22, 2023 |
| 1y Target Est | 108.70 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
GlobeNewswireCytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
Sale of assets related to Flow Cytometry & Imaging (FCI) Business UnitAcquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customersTransaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisitionEmployees associated with commercial, operations, R&D and supporting functions expected to join Cytek SALUGGIA, Italy and FREMONT, Calif., Feb.